Literature DB >> 24029604

Oxaliplatin induced-neuropathy in digestive tumors.

María Sereno1, Gerardo Gutiérrez-Gutiérrez2, César Gómez-Raposo3, Miriam López-Gómez3, Maria Merino-Salvador3, Francisco Zambrana Tébar3, Cristina Rodriguez-Antona4, Enrique Casado5.   

Abstract

Oxaliplatin is one of the main drugs used in digestive tumors treatment. Peripheral neuropathy is a well-recognized dose-limiting toxicity of OXL. Two types of neuropathy have been described with this agent: acute or transient and chronic or persistent, with different etiology, clinical manifestations and prognosis. This paper is an exhaustive review about the main aspects of oxaliplatin induced peripheral neuropathy, focus in clinical features, treatment, prevention strategies and future approach.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Digestive tumors; Oxaliplatin; Peripheral neuropathy

Mesh：

Substances：

Year:  2013        PMID： 24029604     DOI： 10.1016/j.critrevonc.2013.08.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  14 in total

1.  Complex impairment of IA muscle proprioceptors following traumatic or neurotoxic injury.

Authors:  Jacob A Vincent; Paul Nardelli; Hanna M Gabriel; Adam S Deardorff; Timothy C Cope
Journal:  J Anat       Date:  2015-06-05       Impact factor: 2.610

2.  Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study.

Authors:  E Gustafsson; E Litström; C Berterö; J Drott
Journal:  Support Care Cancer       Date:  2015-07-04       Impact factor: 3.603

3.  Engagement of MicroRNA-155 in Exaggerated Oxidative Stress Signal and TRPA1 in the Dorsal Horn of the Spinal Cord and Neuropathic Pain During Chemotherapeutic Oxaliplatin.

Authors:  Fenghua Miao; Rong Wang; Guozhen Cui; Xiaoguang Li; Ting Wang; Xue Li
Journal:  Neurotox Res       Date:  2019-04-23       Impact factor: 3.911

4.  The trajectory of neurotoxic side effects' impact on daily life: a qualitative study.

Authors:  Jenny Drott; Hans Starkhammar; Karin Kjellgren; Carina Berterö
Journal:  Support Care Cancer       Date:  2016-03-19       Impact factor: 3.603

5.  Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain.

Authors:  Zongsheng Duan; Zhenbo Su; Hushan Wang; Xiaochuan Pang
Journal:  Mol Pain       Date:  2018-03-27       Impact factor: 3.395

6.  Topical Delivery of Four Neuroprotective Ingredients by Ethosome-Gel: Synergistic Combination for Treatment of Oxaliplatin-Induced Peripheral Neuropathy.

Authors:  Hong-Mei Lin; Long-Fei Lin; Ming-Yi Sun; Jia Liu; Qing Wu
Journal:  Int J Nanomedicine       Date:  2020-05-07

7.  Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1.

Authors:  Liujun Tian; Tianren Fan; Nan Zhou; Hui Guo; Weijie Zhang
Journal:  Transl Neurosci       Date:  2015-03-18       Impact factor: 1.757

8.  Wen-Luo-Tong Prevents Glial Activation and Nociceptive Sensitization in a Rat Model of Oxaliplatin-Induced Neuropathic Pain.

Authors:  Bo Deng; Liqun Jia; Lin Pan; Aiping Song; Yuanyuan Wang; Huangying Tan; Qing Xiang; Lili Yu; Dandan Ke
Journal:  Evid Based Complement Alternat Med       Date:  2016-08-25       Impact factor: 2.629

Review 9.  Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results.

Authors:  Nuria Mut-Salud; Pablo Juan Álvarez; Jose Manuel Garrido; Esther Carrasco; Antonia Aránega; Fernando Rodríguez-Serrano
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

10.  The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial.

Authors:  Ali Esfahani; Mohammad Hossein Somi; Hormoz Ayromlou; Alireza Nikanfar; Mohammad Asghari Jafarabadi; Bina Eftekhar Sadat; Zohreh Ghoreishi
Journal:  Biomark Res       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.